October 12, 2023

Recent advancements have significantly transformed the treatment landscape for relapsed or refractory classic Hodgkin lymphoma. The emergence of innovative therapies promises better outcomes and sets the path for personalized treatment strategies. Classic Hodgkin lymphoma cure rates have improved with chemotherapy, yet 10–30% of patients experience relapse or refractory disease. The last decade has witnessed the...

A comprehensive analysis of four clinical trials found that anti-programmed cell death-1 therapies may have long-term survival benefits in patients with relapsed or refractory classical Hodgkin lymphoma. However, results varied based on disease status and depth of remission, which may indicate a need for targeted treatment strategies. Anti-programmed cell death-1 therapies can prolong survival in...

Significant metabolic and endocrine disturbances have been found in survivors of childhood-onset acute lymphoblastic leukemia or aggressive non-Hodgkin’s lymphoma treated with cranial radiotherapy. A recent meta-analysis emphasizes monitoring for potential long-term complications in these patients. Childhood-onset and cranial radiotherapy-treated acute lymphoblastic leukemia or aggressive non-Hodgkin’s lymphoma survivors are more likely to have reduced height, precocious...

In a recent editorial, the authors raise concern that baricitinib, the first drug approved to treat alopecia areata, was not adequately tested in people of color. Additionally, its higher cost may further contribute to health disparities. The introduction of baricitinib can be described as a game-changer for the treatment of alopecia areata (AA). Until now,...

Staff Writer: Andre McGowan A retrospective study found that axillary ultrasound falsely predicted nodal response to neoadjuvant systemic treatment in approximately half of node-positive breast cancer patients, which may result in the overtreatment of breast cancer patients. However, the interpretation of axillary ultrasound in luminal human epidermal growth factor receptor 2 negative cancer is useful...

Elevated levels of H3.1-nucleosomes in patients with non-Hodgkin lymphoma could have potential as diagnostic biomarkers. The epigenetic profiles of these nucleosomes may be useful for more effective diagnosis and treatment monitoring, according to a recent study. Elevated H3.1 nucleosome levels correlate with non-Hodgkin lymphoma (NHL), distinguishing patients from healthy donors. Epigenetic profiles of nucleosomes, especially...

Various factors influencing the health-related quality of life of non-Hodgkin lymphoma survivors were revealed in a recent study. The study results highlight the links between socio-demographics, clinical attributes, and psychological conditions. This research provides a comprehensive perspective, potentially influencing tailored interventions in the future. Non-Hodgkin lymphoma survivors show distinct health-related quality of life (HRQoL) challenges....

A recent study provides clarity on age-, gender-, and race-associated disparities in multiple myeloma incidence. The core finding is that differences largely stem from a preceding condition more common in specific groups. Multiple myeloma often develops following a premalignant, asymptomatic condition called monoclonal gammopathy of undetermined significance.  Multiple myeloma shows varying incidence rates among different...

A recent study examined how frequently the V122I genetic variant leads to heart failure in older Black individuals. This research sought to identify how specific genes can influence the development and presentation of transthyretin amyloid cardiomyopathy. Transthyretin amyloid cardiomyopathy (ATTR-CM) remains an underdiagnosed cause of heart failure among older individuals. The V122I variant, associated with...